Table 1.

The studies of CA 125 levels in ULMS and ULM group.

The Authors of the Study	The Year of the Study	Research Group	Main Findings
Duk et al. [35].	1994	33 (30 evaluable patients) with sarcoma	12 out of 30 (40% of patients with uterine sarcoma) showed serum CA 125 levels higher than 16 Uml-1. No correlation between serum CA 125 levels and the histologic subtype was found.
Juang et al. [36].	2006	42 patients with ULMS, 84 patients with ULM	Serum CA125 levels were significantly higher in the uterine ULMS group than CA 125 in the ULM group The correlation between CA 125 levels and stage of the ULMS was described.
Yilmaz et al. [37].	2009	26 patients with uterine sarcoma and 2382 patients with ULM	No correlation between CA 125 levels and uterine sarcoma and ULM.
Skorstad et al. [38].	2016	86 patients with ULMS	CA 125 levels higher than 75 kU/L corresponded to more advance stage of disease (FIGO stage IV) compared to the group with CA 125 levels lower than 75 kU/L.
Zhang Fenfen et al. [39].	2021	37 patients with ULMS, 102 patients with degenerated ULM	CA 125 used as one of the LMS indicators may be a promising method to differentiate ULMS and ULM preoperatively.